Study for treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)

Primary disease category: Cancer

Secondary disease categories: Leukemia & Lymphoma, Myeloma

Sponsor: Southwest Oncology Group

Protocol number: S1117

Projected enrollment dates: January 2014 to April 2020

Official study title: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)